BHC Bausch Health Companies Inc.
USHealthcareAs of 2026-07-10 16:00
Why BHC matters now
Bausch Health Companies Inc. (BHC) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.78 with -1.65% on the session and $1.79B in market capitalization; recent performance reads 1-month -10.34% and YTD -31.37%.
The latest financial table shown here is Q1 2026, with revenue of $2.49B, net income of $-1.40B, and EPS of $-3.79. Investors can compare that operating picture with valuation signals such as P/E 13.36 and FCF yield 55.5%.
The latest indexable market news headline is "Bausch to stop glaucoma eye drop development after trial miss" from Reuters.
Additional event context on this page matters because analyst consensus is Hold with a median target of $8.00; recent insider activity includes Garcia Christian A filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
13.36
PEG
0.03
P/B
-0.86
P/S
0.17
EV/EBITDA
10.82
DCF Value
$180.94
FCF Yield
55.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.7%
Operating Margin
22.9%
Net Margin
-11.3%
ROE
120.7%
ROA
-4.9%
ROIC
11.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.49B | $-1.40B | $-3.79 |
| Q4 2025 | $2.84B | $-113.7M | $-0.31 |
| FY 2025 | $10.45B | $159.7M | $0.43 |
| Q3 2025 | $2.65B | $177.0M | $0.47 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$8.00
Target (Median)
$8.00
Target Range
$8.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
CA
Exchange
—
Beta
0.41
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.